As a mage, I just want to pursue the truth

Chapter 157 Cooperation
The intrigue among the Blue Star countries made Zheng Li realize that it was impossible for them to work together as a whole.

Even the cooperation between China and Russia has reservations.

Originally, Zheng Li deliberately left a shortcut in the magic forum, that is, everyone cooperates to purchase technical materials and then share them.

It's just that I didn't expect that even in the face of such a big temptation, the Blue Star countries could not reach a cooperation.

If the road of cooperation fails, there is only competition.

Zheng Li realized that by appropriately increasing the intensity of competition and confining the scope of competition to the field of scientific research, the potential of the Blue Star civilization could be better stimulated.

Cooperation is a bit illusory for the Blue Star civilization where war is an eternal theme.

This may be the nature of intelligent life.Mages also fought endlessly in ancient and medieval times.

Li Wanqing excitedly said: "As long as you agree, I can definitely convince them. Speaking of biological storage servers, we can put all the data of 1000PB on one storage server."

"The subsequent data processing speed can also increase a lot, which is of great benefit to us in processing brain nerve signals."

The brain-computer connection to the mobile phone has been completed for the development of Bluestar's mainstream languages.

As for the brain-computer connection VR, at present, the Chinese and English departments have completed research and development, and other language departments will start research and development according to their market size.

Zheng Li asked: "How about the test data of the brain-computer connection prosthesis in Jiangcheng?"

Li Wanqing: "The test data is very good. At present, all testers have not had accidents caused by errors in the recognition of brain nerve signals."

"However, the clinical trial of prosthetics in the English Department has been transferred from American to South Africa, and American has not passed our clinical trial application."

"The brain-computer connected prosthesis of the Chinese department is ready to apply for production."

Kechuangbio's brain-computer connection technology is non-invasive, so the approval process for medical devices will be faster.

Zheng imagined that a lot of manpower was devoted to the research and development of innovative drugs in the R&D centers of Kechuang Biotech in Jiangcheng and Suzhou.

He asked: "How is the research and development progress of innovative drugs? Have any of them started clinical trials?"

The research and development of innovative drugs is difficult, but the research and development in the field of Kechuang Biotech has been started since its establishment in 19.

It's just that Zheng Li himself made relatively little contribution in this regard.According to the normal timeline, it takes ten years for the research and development of innovative drugs to achieve certain results.

From early research to determining the chemical composition of a new drug, it takes roughly 3 to 6 years, and preclinical research takes 1 to 2 years.

After going through this long process, there are clinical studies and drug approvals.

Domestic pharmaceutical companies generally start with generic drugs first, and it is extremely rare to start with innovative drugs like Kechuang Biotech.

It is a typical example of not bad money.

Li Wanqing replied: "It is still in the screening process of compounds, and there are not many changes."

As the director of the Lion City R&D Center, Li Wanqing went back to Gusu to attend the annual meeting of Kechuangbio, and also met some researchers from other R&D centers.

Whether it is from the internal company forum, or the private circle of friends and chats of researchers, Kechuangbio has not made much progress in the development of innovative drugs.

Several major sectors of Kechuang Biology, brain-computer connection and endorphin are the main sources of profit.

The area of ​​innovative drugs is one that only sees the input but not the output.Executives are insiders in the biomedical space and know this is normal.

But the relevant person in charge will be anxious. With such a large investment, there is no output for a long time, and the right to speak and status within the company must not be high.

If there is any breakthrough progress in research and development, whether it is to increase its influence or win more attention and support, it will definitely be publicized.

Li Wanqing has not heard any sound so far. The colleagues in the entire innovative medicine line are in silent mode. He knows that there is obviously no breakthrough.

This part will definitely be included in the weekly work summary for Zheng Li, but since the innovative drug has not progressed, it will occupy at most one sentence in the work report.

Zheng Li didn't know much about the real situation of innovative drugs.

After listening to Li Wanqing's answer, he said: "Innovative drugs do require a relatively large investment, which is a long-term investment."

"Like the endorphin I made back then, it wasn't considered an innovative drug, it was a generic drug."

Li Wanqing flattered: "Endorphins have been discovered by scientists in the last century, but no one has developed a manufacturing method, let alone a large-scale production method."

"The difficulty of your research results is not lower than that of any innovative drug."

After Endorphin is launched, the revenue and profit of this drug are no less than the top products of any multinational pharmaceutical giant.

It can be said that it is the foundation of science and innovation biology.

As for innovative drugs, even if billions of dollars are invested, it may not be possible to develop the next blockbuster product with similar effects.

Take Pfizer as an example. Before Sildenafil came out, there was a big gap between it and Merck in terms of revenue and profit.

After the release of sildenafil, Pfizer quickly surpassed Merck by relying on this drug alone.Of course, Merck has come back in the past two years.

But sildenafil took Pfizer straight up a notch.

Of course, Kechuang Biotech is different from Pfizer.Since the launch of the brain-computer connected mobile phone, the outside world has seen Kechuang Biotech as a diversified business, not limited to the field of biomedicine.

Zheng Li rationalized his thinking. His hope for Kechuangbiology is to expand its scale, improve its research and development capabilities, and implement it in place according to his research and development ideas when necessary.

Now Kechuang Bio is still in the development stage. After it stabilizes, Zheng Li plans to inspect internal researchers and keep those with high upper limit of ability.

After Huawei's biological storage server became popular, the outside world was discussing it, and the discussion in the industry became more heated.

Especially Sugon, Inspur, Tsinghua Unigroup, and Yangtze River Storage, all of them are practicing companies, and they spend their time suddenly launching satellites.

Why didn't I hear any wind before.

Yangtze River Storage is better, after all, its vice president suddenly went to work in a central enterprise called Deep Blue Storage.

They have guessed what will happen in the domestic storage industry.

It's just that they didn't expect this movement to be a bit beyond their imagination.Before biological storage, I had never heard of any domestic R&D team with mature technology.

The outside world will focus on Huawei, but the industry knows that it is impossible for Huawei to develop biological storage technology by itself.

It's not that they look down on Huawei, they admire Huawei's research and development capabilities, but Huawei has no relevant technical reserves before, and it is completely unreasonable to take out biological storage out of thin air.

Everyone's attention naturally focused on the dark blue storage mentioned at the Huawei press conference.

The investigation did not find out what happened, only that Guan Yang of YMTC went there to become the chairman.

At the same time, the executives of these companies in the industry are also asking around, which team in domestic universities or research institutes that do DNA macromolecule storage has been poached.

I also did not find out the news. The professors who have published papers on DNA storage before have not heard of any resignation recently.

As Guan Yang expected in advance, after Huawei's press conference, he didn't need to come to the door for marketing, and the heads of various companies came to the door one after another.

"Brother Guan, you are too mean. With such an advanced technology of biological storage, don't let us know Sugon first. We, Sugon, also have deep technical accumulation and rich experience in the field of storage servers."

As soon as the chairman of Inspur walked away, the chairman of Shuguang came to the door. Li Jun didn't meander, and got straight to the point.

Sugon is also a state-owned enterprise, but it is not a state-owned enterprise directly managed by the central government. It is an enterprise incubated by the Ministry of Science and Technology and the Huaguo Academy of Sciences.The current actual controller is the Institute of Computing Technology, Huaguo Academy of Sciences.

When Guan Yang was the vice president of YMTC, he was more than one level behind Li Jun.

Guan Yang said with a smile: "The main thing is that our technology has only been developed, and it is not mature enough. There are still many areas for improvement, so I am not ashamed to cooperate with Suguang."

"When I was in Yangtze River Storage, I was not able to cooperate with Sugon because the technology was not mature enough. After coming to Deepblue Storage this time, the main technology is still not mature enough."

What Guan Yang is alluding to is that YMTC hoped to enter Sugon’s supply chain system before, but Sugon has been delaying it on the grounds that YMTC’s technology is not mature enough.

Sugon's storage server supplier has always been American's Seagate.Seagate is the world's largest manufacturer of hard drives and disks.

Technically, Seagate is definitely more mature.

However, YMTC is a key national support project, and YMTC’s appeal at the time was not to directly replace Seagate, but to enter Sugon’s supply chain system, and supply only when it meets the conditions.

Even with such a condition, Shuguang did not agree.

Li Jun knew that Guan Yang was still worried about that matter. He explained: "At that time, we hoped to choose YMTC, but we signed a three-year strategic cooperation agreement with Seagate in 18."

"In addition, YMTC's 64-layer flash memory technology was still immature at the time, and we did not expect YMTC's technological progress to be so fast."

"The 128-layer 3D NAND technology has been conquered in just two years."

Li Jun is purely making excuses, and the strategic cooperation agreement is not an exclusive agreement.YMTC's 64-layer flash memory technology can fully enter Sugon's low-end storage server models first.

Guan Yang didn't expose the other party. He was just looking for excuses to prevaricate the other party. He changed the company. It is impossible to embarrass Li Jun because of some festivals of Yangtze River Storage.

It was only a few days before Guan Yang realized why he was appointed as the chairman of Deep Blue Storage. It was because he was well connected and he was specially sent to reject these requests.

"Understood, when the bio-storage technology matures, we will authorize all Huaguo enterprises."

"You don't have to worry."

"Everyone is a state-owned enterprise, how could our technology not be authorized by Sugon?"

　Thanks to Evergreen 1040, Ijukko Fifth Rotary Arm Central Hub, Wang Wei Huohua, Aoshi Huansheng, and book friends 20201222095310546 for their rewards!
　　
　
(End of this chapter)